The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic Cleft.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  ACS Medicinal Chemistry Letters

• Publication date

  2013-02-14

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/ML300428SPMID 23565325PMCID PMC3615567
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein kinase biochemistry and drug discovery.

  2011cited by this paper
• Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors.

  2010cited by this paper
• Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease.

  2010cited by this paper
• Light Chain Separated from the Rest of the Type A Botulinum Neurotoxin Molecule Is the Most Catalytically Active Form

  2010cited by this paper
• Identification and Biochemical Characterization of Small-Molecule Inhibitors of Clostridium botulinum Neurotoxin Serotype A

  2009cited by this paper
• Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity.

  2009cited by this paper
• The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison.

  2008cited by this paper
• Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations.

  2008cited by this paper
• Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.

  2007cited by this paper
• Botulinum toxin: pharmacology and clinical developments: a literature review.

  2007cited by this paper
• Botulinum toxin: clinical use.

  2006cited by this paper
• Automatic atom type and bond type perception in molecular mechanical calculations.

  2006cited by this paper
• Comparison of multiple Amber force fields and development of improved protein backbone parameters

  2006cited by this paper
• Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.

  2006cited by this paper
• Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors.

  2006cited by this paper
• The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability.

  2004cited by this paper
• Factors Affecting Autocatalysis of Botulinum A Neurotoxin Light Chain*

  2004cited by this paper
• Substrate recognition strategy for botulinum neurotoxin serotype A

  2004cited by this paper
• Exploring protein native states and large‐scale conformational changes with a modified generalized born model

  2004cited by this paper
• Autocatalytically fragmented light chain of botulinum a neurotoxin is enzymatically active.

  2003cited by this paper
• Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective.

  2001cited by this paper
• Enzymatic Autocatalysis of Botulinum A Neurotoxin Light Chain

  2001cited by this paper
• Botulinum toxin as a biological weapon: medical and public health management.

  2001cited by this paper
• Modification of the Generalized Born Model Suitable for Macromolecules

  2000cited by this paper
• Light Chain of Botulinum A Neurotoxin Expressed as an Inclusion Body from a Synthetic Gene Is Catalytically and Functionally Active

  2000cited by this paper
• Neurotoxins affecting neuroexocytosis.

  2000cited by this paper
• Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO)

  1999cited by this paper
• Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation.

  1999cited by this paper
• Tyrosine Phosphorylation Modulates the Activity of Clostridial Neurotoxins*

  1996cited by this paper
• Structure and Function of Clostridium botulinum Toxins

  1995cited by this paper
• C. botulinum neurotoxin types A and E: isolated light chain breaks down into two fragments. Comparison of their amino acid sequences with tetanus neurotoxin.

  1989cited by this paper
• [Structure and function of Clostridium botulinum toxins].

  1988cited by this paper

• Bifunctional Inhibition of Botulinum Neurotoxin A Protease: Unexpected Active Site Inhibition Enhances Covalent Targeting of an Allosteric Site.

  2025cites this paper
• Zinc enzymes in medicinal chemistry.

  2021cites this paper
• Biologically Active Compounds of Plants: Structure-Related Antioxidant, Microbiological and Cytotoxic Activity of Selected Carboxylic Acids

  2020influential citation
• A novel role of C-terminus in introducing a functionally flexible structure critical for the biological activity of botulinum neurotoxin

  2018cites this paper
• Targeting Metalloenzymes for Therapeutic Intervention.

  2018cites this paper
• Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A

  2017cites this paper
• Newly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based, and ex Vivo Assays.

  2017cites this paper
• Solubility of the catalytic domains of Botulinum neurotoxin serotype E subtypes.

  2016cites this paper
• High-Throughput Screening Uncovers Novel Botulinum Neurotoxin Inhibitor Chemotypes.

  2016cites this paper
• Molecular dynamics simulations of wild type and mutants of botulinum neurotoxin A complexed with synaptic vesicle protein 2C.

  2015cites this paper
• Probing BoNT/A Protease Exosites: Implications for Inhibitor Design and Light Chain Longevity

  2014cites this paper
• High-throughput screening technologies for botulinum neurotoxins.

  2014cites this paper
• Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening

  2014cites this paper
• Benzoquinones as inhibitors of botulinum neurotoxin serotype A.

  2014cites this paper
• Basic Chemistry of Botulinum Neurotoxins Relevant to Vaccines, Diagnostics, and Countermeasures

  2014cites this paper
• The C Terminus of the Catalytic Domain of Type A Botulinum Neurotoxin May Facilitate Product Release from the Active Site*

  2013cites this paper
• Site Facilitate Product Release from the Active Type A Botulinum Neurotoxin May The C Terminus of the Catalytic Domain of Enzymology

  2013cites this paper